The short isoform of single-minded 2 (SIM2s), a basic helix-loop-helix/PAS (bHLH/PAS) transcription factor, is upregulated in pancreatic and prostate tumours; however, a mechanistic role for SIM2s in these cancers is unknown. Microarray studies in prostate DU145 cells identified the pro-cell death gene, BNIP3 (Bcl-2/adenovirus E1B 19 kDa interacting protein 3), as a novel putative target of SIM2s repression. Further validation showed BNIP3 repression in several prostate and pancreatic carcinoma-derived cell lines with ectopic expression of human SIM2s. BNIP3 levels are enhanced in prostate carcinoma cells upon short interfering (si)RNA-mediated knockdown of endogenous SIM2s. Chromatin immunoprecipitation and promoter studies show that SIM2s represses BNIP3 through its activities at the proximal promoter hypoxia response element (HRE), the site through which the bHLH/PAS family member, hypoxia-inducible factor 1a (HIF1a), induces BNIP3. SIM2s attenuates BNIP3 hypoxic induction via the HRE, and increased hypoxic induction of BNIP3 occurs with siRNA knockdown of endogenous SIM2s in prostate PC3AR þ cells. BNIP3 is implicated in hypoxia-induced cell death processes. Prolonged treatment of PC3AR þ cells with hypoxia mimetics, DP and DMOG, confers hypoxia-induced autophagy, measured by enhanced LC3-II levels and SQSTM1/p62 turnover. We show that PC3AR þ cells expressing ectopic SIM2s have enhanced survival in these conditions. Induction of LC3-II and turnover of SQSTM1/p62 are attenuated in PC3AR þ / SIM2s DMOG and hypoxia-treated cells, suggesting that SIM2s may attenuate autophagic cell death processes, perhaps through BNIP3 repression. These data show, for the first time, SIM2s cross-talk on an endogenous HRE. SIM2s' functional interference with HIF1a activities on BNIP3 may indicate a novel role for SIM2s in promoting tumourigenesis.
Introduction
Single-minded 2 (SIM2) is a member of the basic helixloop-helix (bHLH)/PAS (Per-Arnt-Sim) family of transcriptional regulators (Kewley et al., 2004) for which functions remain to be determined. Targeted deletion of SIM2 in mice results in scoliosis, major disruptions in craniofacial structures and death shortly after birth owing to a breathing defect (Goshu et al., 2002; Shamblott et al., 2002) , which shows that it has important roles during development. Alternative splicing produces a short (SIM2s) protein variant in mice and humans (Chrast et al., 1997; Metz et al., 2006) . The human SIM2s (hSIM2s) splice variant arises from an alternate readthrough event into the last intron of SIM2, resulting in a 570-amino-acid protein that contains only one of the two SIM2 repression regions and a final 44 residues of the unique C-terminal sequence (Chrast et al., 1997) . How the minor divergence between the C-termini of full-length SIM2 (SIM2long or SIM2l) and SIM2s may confer alternate transcriptional activities or functions remains to be investigated.
SIM2 heterodimerizes with the common bHLH/PAS partner factor, aryl hydrocarbon receptor nuclear translocator (ARNT) (Probst et al., 1997) , to bind DNA. Most of the current understanding of SIM2/ARNT transcriptional activities comes from studies of the mSIM2 long isoform. Cell-based reporter gene assays have shown the murine long isoform to mediate repression of transcription via carboxy-terminal repression domains (Ema et al., 1996b; Moffett et al., 1997; Woods and Whitelaw, 2002) . Recently, hSIM2s-mediated repression of the SLUG gene in breast cancer cells has been reported (Laffin et al., 2008) . Another repressive mode of SIM2 is by sequestration of ARNT from other bHLH/PAS transcription factors, a mechanism by which SIM2 can interfere with the function of the hypoxia-inducible factor 1a (HIF1a) (Woods and Whitelaw, 2002) . Conversely, on some promoters, the SIM2/ARNT heterodimer can activate transcription via the transactivation domain of ARNT (Metz et al., 2006; Woods et al., 2008) . The expression status of SIM2s is emerging as an interesting candidate for a solid tumour marker. Select up-regulation of SIM2s has been identified in solid tumours of the pancreas, colon and prostate (DeYoung et al., 2002 (DeYoung et al., , 2003b Aleman et al., 2005; Halvorsen et al., 2007) . Although the focus has mainly been on SIM2s in these tumour types, SIM2l messenger RNA (mRNA) has also been found to be expressed in tumours and tumour-derived cell lines of the pancreas (DeYoung et al., 2003b) and in prostate tumours (Halvorsen et al., 2007) , but not in the corresponding normal cell lines or benign tissue samples. Several independent microarray studies have found SIM2 to be the second most consistently up-regulated gene in prostate tumours, while not being expressed in the corresponding benign tissue (Su et al., 2002; Chandran et al., 2005; Halvorsen et al., 2007) . SIM2 over-expression in human pancreatic carcinoma samples and derived cell lines compared with normal ductal epithelium controls has also recently been found in the most comprehensive genome-wide analysis to date (Jones et al., 2008) . Compellingly, Halvorsen et al. (2007) found that elevated SIM2s protein levels significantly correlated with increased prostate tumour aggression and a marked decrease in estimated survival. Thus, the authors propose SIM2s levels as a novel marker of aggressive prostate cancer. Studies by Narayanan and colleagues have strongly linked SIM2s expression with the survival of tumour-derived cell lines of the pancreas and colon, where antisense-mediated knockdown of SIM2s in cell culture and mouse xenograft models results in cell death and a decrease in tumour size (DeYoung et al., 2002 (DeYoung et al., , 2003a Aleman et al., 2005) . Conversely, however, SIM2s has recently been found to be repressed in breast cancer tumours (Kwak et al., 2007) . In contrast to the colon and pancreatic tumour-derived cell lines tested, loss of SIM2s in MCF-7 breast cancer cells correlates to cell survival through the activation of SLUG-mediated EMT (epithelial-mesenchymal transition) (Kwak et al., 2007; Laffin et al., 2008) . Whether changes in SIM2s expression levels are required for tumour growth and/or tumour maintenance, and how SIM2s expression and transcriptional activities fit into the molecular profile of disease progression, is in need of further investigation.
In this study, we sought to identify novel SIM2s target genes as a means to investigate the role(s) of SIM2s activity in tumour progression. We report that the HIF1a-dependent, hypoxically induced pro-apoptotic Bcl-2 BH3-only subfamily member, BNIP3 (Boyd et al., 1994; Bruick, 2000; Sowter et al., 2001) , is a novel target of SIM2s. We also provide the first evidence of SIM2s cross-talk on a hypoxia response element (HRE) in an endogenous target gene. The SIM2s-mediated repression of BNIP3, which has recently emerged as a proautophagic factor (Tracy et al., 2007a; Azad et al., 2008; Zhang et al., 2008) , is coupled to the role of SIM2s in increasing prostate tumour-cell survival during prolonged hypoxic conditions. Our data indicate that one mechanism of survival may be through the attenuation of autophagic cell death processes that require BNIP3.
Results and discussion

Identification of BNIP3 as a putative target of repression by SIM2s
To investigate the effects of aberrantly high levels of SIM2s, we initially analysed SIM2s mRNA expression in common prostate and pancreatic carcinoma cell lines by semi-quantitative reverse transcription (RT)-PCR. This revealed a slightly lower expression of endogenous SIM2s in the human prostate carcinoma DU145 cells compared with other prostate and pancreatic carcinoma cell lines (Figure 1a) . Consequently, independently derived polyclonal cell pools showing stable ectopic expression of carboxy-terminal myc-tagged human SIM2s (SIM2s.myc) were generated in DU145 cell line to emulate an aberrant increase in SIM2s in prostate cancers compared with benign samples, as previously observed from several studies by others (Su et al., 2002; Chandran et al., 2005; Halvorsen et al., 2007) . Puromycin-resistant control (Control) pools were generated by incorporation of the empty expression vector. Co-immunoprecipitation experiments revealed that endogenous ARNT1 dimerizes with SIM2s.myc in the derived cells, and importantly, analysis of supernatant following immunoprecipitation showed that ARNT1 protein remained in excess of SIM2s in these cells (Supplementary Figure S1) . Thus, further ectopic expression of the obligate partner factor ARNT1 was not required to obtain complete heterodimerization of ectopic SIM2s.myc. To discover SIM2s target genes that may relate to cancer progression, we performed microarray analyses of independently derived polyclonal cell lines of DU145/SIM2s.myc versus puromycin-resistant control cells. These experiments revealed down-regulation of BNIP3 mRNA upon ectopic expression of SIM2s, which was independently validated by semiquantitative RT-PCR in DU145/SIM2s.myc stable expressing cells that were not used for the microarray study ( Figure 1a ). BNIP3 has long been regarded as a pro-apoptotic Bcl-2 family member (reviewed in Lee and Paik (2006) and Burton and Gibson (2009) ). Silencing of BNIP3 correlates to increased pancreatic and colon tumour cell survival in vitro, and tumour progression, chemoresistance and worsened prognosis in vivo (de Angelis et al., 2004; Okami et al., 2004; Akada et al., 2005; Erkan et al., 2005; Bacon et al., 2007; Ishiguro et al., 2007; Mahon et al., 2007) . Notably, these are two of the tumour types in which SIM2s is found to be aberrantly up-regulated (DeYoung et al., 2002 (DeYoung et al., , 2003a . Unfortunately, there is no current understanding of how regulation of BNIP3 affects prostate cancer progression and patient outcomes. However, these findings suggest a putative role for SIM2s in cancer by way of repression of BNIP3, with inhibition of BNIP3-mediated cell death being a possible mechanism of tumour progression. We have further validated BNIP3 repression upon stable ectopic expression of SIM2s in other human prostate carcinoma-derived cell lines and pancreatic cancer lines (Figure 1a ). Repression was evident at both the message and protein levels in these carcinoma-derived cell lines (Figures 1a and b, respectively) . Stable and transient expression of hSIM2s also repressed mBNIP3 expression in mouse NIH3T3 fibroblasts and mouse P19 embryonic carcinoma cells, respectively (Figure 1a ). Short interfering (si)RNA-mediated knockdown of stably expressed SIM2s, using two independent siRNA oligonucleotides, alleviated BNIP3 repression as shown by western analysis in PC3AR þ /SIM2s.myc cells (Figure 1c ). Likewise, BNIP3 levels were enhanced upon treatment of parent prostate PC3AR þ and DU145 cells for specific siRNA-mediated knockdown of endogenous SIM2s in a consistently moderate manner at the protein level ( Figure 1d ) and as shown for DU145 cells, at the mRNA level ( Figure 1e ). Taken together, these data strongly indicate that BNIP3 silencing occurs downstream of SIM2s activity.
Silencing of BNIP3 has previously been found to occur through hypermethylation of the CpG island contained in the regulatory region of the human BNIP3 promoter in colon and pancreatic tumours (Okami et al., 2004; Murai et al., 2005; Bacon et al., 2007) ; however, we found no change in promoter methylation with SIM2s ectopic expression in prostate DU145 cells, using epigenetic genomic DNA sodium bisulphite conversion and sequencing techniques (data not shown). We therefore aimed to investigate the potential direct mechanisms of SIM2s transcriptional repression of BNIP3. SIM2 has been shown to exhibit cross-talk with HIF by binding to the EPO HRE in a synthetic reporter Figure 1 Ectopic expression of human (h) myc-tagged human SIM2s (SIM2s.myc) represses BNIP3 across human prostate and pancreatic carcinoma, and mouse, derived cell lines. (a) Semi-quantitative RT-PCR analysis of BNIP3, SIM2s and GAPDH (loading control) messenger RNA (mRNA) levels in hSIM2s.myc-expressing prostate (DU145, LNCaP, PC3AR þ ) and pancreatic (PANC-1, CFPAC) cancer cell line pools, and mouse fibroblast NIH3T3 and embryonic carcinoma P19 cells, compared with empty-vector or untransfected control cells. Primer sequences and PCR conditions are described in Supplementary information. No RT ¼ no reverse transcriptase. PCR Àve ¼ no cDNA template. Single amplicons were identified by 1% agarose electrophoresis. (b) Immunoblot analysis of BNIP3, hSIM2.myc and aTubulin (loading control) protein in hSIM2.myc stable human prostate and pancreas carcinoma cell lines. Whole cell extracts (WCE) were separated by 12% SDS-PAGE, followed by sequential immunoblot detection of proteins as indicated. (a and b) Representative of n ¼ 2-3 independently derived polyclonal cell lines for each cell type. (c) Repression of BNIP3 is alleviated on short interfering (si)RNA knockdown of ectopic hSIM2s.myc. Two independent short interfering (si)RNA oligonucleotides, siSIM2s-1759 and siPanSIM2-2, and a scrambled control short interfering (si)RNA were used to treat PC3AR þ / SIM2s.myc cells in 2 Â 100 nm doses 24 h apart. WCE were harvested 72 h after first treatment and separated by 12% SDS-PAGE, followed by sequential immunoblot analysis of BNIP3, hSIM2s.myc, and aTubulin as loading control. Representative of n ¼ 3. BNIP3 levels are enhanced in a manner consistent with siRNA-mediated knockdown of endogenous SIM2s. (d) Western analysis of BNIP3 levels in parent PC3AR þ and DU145 cell lines following transfection of siSIM2s-1759. Representative of n ¼ 2 for each cell line. (e) Quantitative-PCR assessment of the fold change in BNIP3 mRNA levels following induced expression of siSIM2s-1759 in DU145 cells. n ¼ 3, error bars, s.e.m. Cell culture conditions, siRNA oligo sequences, transfection and PCR conditions, and sources of antibodies and reagents are described in Supplementary information.
SIM2s repression of the pro-cell death gene, BNIP3 AL Farrall and ML Whitelaw gene (Woods and Whitelaw, 2002) . We therefore investigated the previously identified HRE (5 0 -CACG TG-3 0 ) (Bruick, 2000; Okami et al., 2004; Tracy et al., 2007a) in the proximal promoter of BNIP3 as a putative site for SIM2s binding (also see Figure 2a ). We bioinformatically identified further possible sites through which SIM2s might directly mediate repression of BNIP3, in particular, the novel S2RE (SIM2 response element), recently identified by us in the promoter of Myomensin2 (Woods et al., 2008) . Intriguingly, a putative S2RE was found to be conserved within the first intron of BNIP3 in human, rat and mouse genes, in a positional manner as is the HRE (Figure 2a ). We termed this S2RE 'site 1'. Other putative S2RE sites were identified upstream of the HRE in the rat, and a second S2RE (site 2) downstream of S2RE site 1 in the mouse (Figure 2a ).
SIM2s binds to the HRE, and not the intronic S2RE, in the proximal promoter of BNIP3 Bioinformatic analysis of the region of the mouse BNIP3 promoter corresponding to the CpG island in the human promoter showed a markedly reduced CG content (data not shown), making it ultimately a more amenable region for PCR analysis of chromatin immunoprecipitation (ChIP) assays and the generation of BNIP3 promoter luciferase reporter constructs. We used these methods to initially examine whether the mechanism of SIM2s repression of BNIP3 was through direct binding at the identified HRE and S2REs (Figure 2a ). Stably expressed hSIM2s in mouse NIH3T3 cells results in mBNIP3 repression as observed in human carcinoma cell lines (Figures 1a and 3a) . We found that human SIM2s bound to the proximal promoter HRE, and interestingly, not the downstream intronic S2REs of the mBNIP3 promoter in normoxic growth conditions by ChIP (Figure 2b ). HIF1a binding at these sites was not examined as HIF1a protein is rapidly degraded in normoxia (Semenza, 2000) and is not detectable in these cells in these growth conditions (Figure 3a) , nor do ChIP studies by others find HIF1a to be bound to the BNIP3 promoter in normoxia (Tracy et al., 2007a) . Luciferase gene expression, under the control of 1 kb of the mBNIP3 promoter (Figure 2a ) in NIH3T3 cells, shows that SIM2s transcriptional repression requires a functional HRE, as HRE mutant constructs fail to be repressed, despite the presence of a functional S2RE (Supplementary Figure S2) . Taken together, this shows, for the first time, the functional SIM2s recognition of an endogenous HRE.
SIM2s attenuates the hypoxic induction of BNIP3 BNIP3 is hypoxically up-regulated in a wide variety of tumours and tumour-derived cell types (Mellor and Harris, 2007) and has long been established as a target gene of HIF1a/ARNT1 via its binding to the HRE in the proximal promoter (Bruick, 2000) . To ascertain whether SIM2s-mediated repression of BNIP3 via the HRE seen in normoxic growth conditions has any impact on the ability of hypoxia to induce BNIP3, Figure 2 SIM2s binds the proximal promoter hypoxia response element (HRE), and not the intronic S2RE (SIM2 response element), in the regulatory region of the BNIP3 gene in normoxia. (a) Bioinformatic identification of putative SIM2s binding sites in the regulatory regions of human, rat and mouse BNIP3. Previously identified canonical HRE (5 0 -CACGTG-3 0 ) (Bruick, 2000) in the proximal promoter is conserved in a positional manner in rat and mouse. Also conserved is a SIM2 response element (S2RE) (5 0 -AACGTG-3 0 ), found in all species inside intron 1, denoted 'site 1' in mouse. Primer sites for PCR analysis of human (h)SIM2s binding activities from chromatin immunoprecipitation (ChIP) studies are indicated. The 1-kb mBNIP3 promoter region containing the HRE and S2RE for driving expression of luciferase reporter gene in pGL3-Basic is outlined, along with HRE, S2RE and double (Dble) mutant constructs. (b) Human SIM2s binds the proximal promoter HRE, but not downstream intronic S2REs (site 1 and 2), of BNIP3. ChIP analyses (see Supplementary information) were performed using NIH3T3 cells with stable myc-tagged human SIM2s (hSIM2s.myc) expression, with anti-hSIM2s antibody. Single amplicons were identified by 2.5% agarose gel electrophoresis. PCR analysis of the first intronic region of mouse b-ACTIN serves as a negative and background loading control, as do immunoprecipitations with IgG antibody or no antibody. 1% input chromatin is included as a positive PCR control. The results are representative of two independent experiments. SIM2s repression of the pro-cell death gene, BNIP3 AL Farrall and ML Whitelaw human prostate carcinoma and mouse fibroblast cells stably expressing hSIM2s were subjected to 16-h growth in a hypoxic chamber (p0.2% O 2 ) and BNIP3 protein levels assessed by western blot analysis. Across all lines, although hypoxic induction of HIF1a was clearly seen (Figure 3a) , induction of BNIP3 was attenuated in hSIM2s.myc-expressing cells as compared with Control cells (Figure 3a) . This suggests that SIM2s may directly interfere with HIF1a activities in hypoxia. This interference appears to exist despite the marked reduction of SIM2s.myc protein levels during hypoxic treatment (Figure 3a , panel set ii). This reduction in SIM2 protein levels during hypoxia has been observed previously, presumably as a result of hypoxia-induced global reduction in translation (Woods and Whitelaw, 2002) . Consistent with ectopic SIM2s attenuation of hypoxic BNIP3 induction, siRNA-mediated knockdown of endogenous SIM2s mRNA in PC3AR þ cells results in a moderate increase in the hypoxic induction of BNIP3 mRNA (Figure 3b) . Together, these studies indicate an endogenous role for SIM2s in the regulation of BNIP3.
SIM2s attenuates hypoxic induction of BNIP3 via activities when bound to the HRE
Following from the observation that SIM2s expression is correlated with an attenuation in hypoxic induction of BNIP3 (Figure 3a) , we sought to investigate whether these conditions led to alternate mechanisms, and/or sites of activity, of SIM2s-mediated repression. To examine whether the binding site profile of SIM2s to the BNIP3 regulatory region changed in hypoxia, subconfluent NIH3T3 cells with and without stable expression of hSIM2s.myc were treated with hypoxia and subsequently used for ChIP analysis of HIF1a and hSIM2s.myc binding on the endogenous BNIP3 regulatory region. Clear PCR enrichment for endogenous HIF1a binding at the HRE in the control cells was observed, but HIF1a was not found to bind to the downstream putative S2RE (Figure 3c ). Likewise, transient transfection of the luciferase reporter gene containing the 1-kb mBNIP3 promoter (Figure 2a ) for 24 h followed by a final 16 h of hypoxia showed that hypoxic induction of the promoter requires the HRE, whereas the S2RE alone is unable to mediate hypoxic induction of the reporter gene (Figure 3d , compare columns a and e). Interestingly, in NIH3T3/hSIM2s.-myc cells, both endogenous HIF1a and hSIM2s were found to be present at the HRE, and again, not at the downstream intronic putative S2RE (Figure 3c) , by ChIP. This shows that the absolute preference of hSIM2s for the HRE does not change in hypoxia. Consistent with stable ectopic expression of SIM2s attenuating hypoxic induction of BNIP3 in human carcinoma and mouse fibroblast cells (Figure 3a) , transient expression of hSIM2s markedly attenuated the hypoxic induction of the mBNIP3 promoter-driven reporter gene. This activity required the presence of the functional HRE, whereas the downstream S2RE was not required, nor was sufficient, to mediate regulation ( Figure 3d ; reporter construct 1, compare columns a and c; reporter construct 2, e and g).
SIM2s may also repress BNIP3 through ARNT sequestration from HIF1a SIM2 has previously been shown to also mediate repression of synthetic HRE-driven promoters by functional interference of HIF1a activities through the sequestration of ARNT (Woods and Whitelaw, 2002) . The addition of hARNT1 with hSIM2s partially alleviated hSIM2s-mediated repression of the hypoxically induced mBNIP3 promoter (Figure 3d , compare columns c and d). These data suggest that SIM2s-mediated repression of BNIP3 in hypoxia may also involve competition for ARNT from HIF1a. This is the first evidence of SIM2s repression in the regulation of an endogenous target gene using this mechanism.
SIM2s expression protects from prolonged hypoxia mimetic-induced cell death in human prostate carcinoma PC3AR þ cells Prolonged hypoxia induces cell death via an autophagic pathway involving the HIF1a-mediated up-regulation of BNIP3 (Tracy et al., 2007a; Azad et al., 2008) . Autophagy is a cellular response to stressful stimuli, such as hypoxia and starvation, which can result in either cell survival or cell death outcomes, reflected in the evidence from cancer studies, in which autophagy has roles in both tumour suppression and tumour growth (for reviews, see Levine (2007) and Maiuri et al. (2007) ). The precise molecular mechanisms that occur in response to specific stress stimuli and/or tumour microenvironment, and that regulate autophagy to either prevent or promote tumourigenesis, remain to be determined. BNIP3 is one factor that has been found to be required to mediate autophagic cell death in response to hypoxia through HIF1a activities (Daido et al., 2004; Tracy et al., 2007a; Azad et al., 2008) . The loss of BNIP3 in pancreatic and colon tumours, either by hypermethylation or by transcriptional repression, is correlated with inhibition of cell death (Okami et al., 2004; Murai et al., 2005; Bacon et al., 2007; Mahon et al., 2007) , whereas up-regulation of BNIP3 sensitizes pancreatic carcinoma cells to hypoxia-induced cell death (Abe et al., 2005) . Aleman et al. (2005) have shown that cell death resulting from SIM2s antisense treatment of colon cancer RKO cells was apoptotic, being largely dependent on the activities of caspases 9 and 10; however, mechanisms of autophagy have not been investigated. Autophagic and apoptotic cell death programmes are not mutually exclusive, and BNIP3 has been implicated in both mechanisms (for reviews, see Maiuri et al. (2007) and Burton and Gibson (2009) ). Thus, we next investigated whether SIM2s expression, concomitant with its repression of BNIP3, enhances tumour cell survival under prolonged hypoxic conditions. Recently, the enhanced degradation of sequestosome 1 (SQSTM1/p62) has been found to occur under conditions of hypoxia-induced autophagy Figure 3 SIM2s attenuates hypoxia-inducible factor 1a (HIF1a)-mediated hypoxic induction of BNIP3 via the hypoxia response element (HRE). (a) Prostate DU145, LNCaP and PC3AR þ carcinoma derived cells, and mouse fibroblast NIH3T3 cells with, and without, stable ectopic expression of human (h) myc-tagged human SIM2s (SIM2s.myc) were subjected to 16-h growth in a hypoxic chamber (H) or normoxic (N) growth conditions. Whole-cell extracts were then separated by 12% (i) and 8% (ii) SDS-PAGE, followed by immunoblot analysis of BNIP3, HIF1a, SIM2s.myc and aTubulin for loading control. Representative of n ¼ 2-3 for each cell line. (b) Parent PC3AR þ cells were treated with either a scrambled control short interfering (si)RNA or SIM2s specific short interfering (si)RNA, siSIM2s-1759, 2 Â 100 nM, 24 h apart, then harvested for total RNA 72 h after the first treatment, during which the final 16-h growth was in hypoxic conditions, as described above. Quantitative real-time PCR analysis for endogenous BNIP3 and SIM2s messenger RNA (mRNA), normalized to POL2Ra mRNA levels using 'QGene' software (Muller et al., 2002) , and graphed as the average percent fold change from the respective scrambled short interfering (si)RNA controls. Control levels ¼ 100%. n ¼ 4. (c) Chromatin immunoprecipitation (ChIP) analyses were performed with HIF1a and hSIM2s antibodies using NIH3T3 cells without (Control), or with stable hSIM2s.myc expression, following 8 h growth in a hypoxic chamber (p0.2% O 2 ). Single amplicons were identified by 2.5% agarose gel electrophoresis. PCR analysis of chromosome 7 (Chr7), a region 3 kb upstream of the mBNIP3 promoter, serves as a negative and background loading control, as do immunoprecipitations with IgG antibodies. 1% input chromatin is included as a positive PCR control. The results are representative of two independent experiments. (d) Subconfluent NIH3T3 cells were transiently transfected with mBNIP3 promoter constructs with or without hSIM2s.myc and/or hARNT1.HA (C-terminal haemagglutinin-tagged hARNT1). After 24-h growth, cells were subjected to 16-h hypoxia, then relative luciferase reporter activity, normalized to co-transfected b-galactosidase levels, was determined. Data are represented as average fold change above pGL3-Basicempty vector controls. n ¼ 4. (b and d) All error bars, s.e.m. Unpaired two-tailed Student's t-test. Significance: **Pp0.01. n.s., no significance. Cells culture conditions, hypoxia treatments, plasmid constructs, siRNA oligonucleotide sequences and transfection conditions, ChIP method, primer sequences for qPCR analysis and PCR conditions, sources of antibodies and regents have been described in the Supplementary information.
SIM2s repression of the pro-cell death gene, BNIP3 AL Farrall and ML Whitelaw (Pursiheimo et al., 2009) . Reduced protein levels of SQSTM1/p62 were found following prolonged (44 h) treatment of human prostate PC3AR þ cells with hypoxia ( Figure 4eii, compare lanes 1 and 3) , and the hypoxia mimetics dimethyloxallyl glycine (DMOG, a hydroxylase inhibitor), consistent with previous reports 6 ± 2.9-fold induction, compared with lane 4 plus SIM2s.myc ¼ 0.96 ± 0.5-fold; average fold change ± s.e.m.; n ¼ 3-4) and the turnover of SQSTM1/p62 (eii) compared with controls. Whole-cell extracts from cells treated for 44 h, as described above, were separated by (a) 10%, (c, ei) 12% or (d, eii) 15% SDS-PAGE, followed by immunoblot analysis of (a, eii) SQSTM1/p62, (c) BNIP3, or (d, ei) LC3-II protein levels, and aTubulin or Actin as loading controls. Quantification of (c) BNIP3 from chemiluminescent immunoblot analyses of three independent experiments, normalized to aTubulin load control, and likewise LC3-II protein levels (dii, e) normalized to aTubulin and a non-specific anti-LC3B background band (B36 kDa), with densitometry was performed using ImageQuant v5.2 software. n ¼ 3-4. All error bars, s.e.m. Unpaired, two-tailed Student's t-test used. Significance: *Pp0.05, **Pp0.01, ***Pp0.001. Values of non-statistically significant P values are also indicated. Cell culture conditions, sources of antibodies and reagents have been described in Supplementary information.
SIM2s repression of the pro-cell death gene, BNIP3 AL Farrall and ML Whitelaw (Pursiheimo et al., 2009) , and dipyridyl (DP, an iron chelator) (Figure 4a ), indicating the induction of autophagy in these cells. As found in hypoxia (Figure 3a) , treatment with the hypoxia mimetics induced BNIP3 protein levels ( Figure 4c , compare columns 1 and 5 with column 3). Using a WST-1 reagent assay system that quantifies mitochondrial function as a measure of cell survival and growth, we found that ectopic expression of SIM2s.myc in human prostate PC3AR þ cells resulted in increased cell survival in these conditions (Figure 4b ). Cells expressing SIM2s.myc maintained significantly higher mitochondrial function from 18 to 36 h of DP treatment, whereas control cell viability decreased markedly by 36 h (Figure 4b ). Intriguingly, from 18 to 36 h of DMOG treatment, SIM2s.mycexpressing cells showed an increase in mitochondrial function (Figure 4b ), indicating cell proliferation. Ultimately, PC3AR þ /SIM2s.myc cells were able to maintain increased cell survival and mitochondrial function above PC3AR þ /control cells in hypoxiaactivated autophagic conditions induced by 44 h of prolonged treatment with either of the hypoxia mimetics, and was concomitant with maintained SIM2s-mediated repression of BNIP3 (Figures 4b and c) . To ascertain whether SIM2s-enhanced cell survival occurs through attenuation of hypoxia-induced autophagic cell death processes that are reported to be mediated by BNIP3 (Tracy et al., 2007a; Azad et al., 2008) , we specifically analysed the processing and induction of protein levels of the autophagy marker, LC3-II (Mizushima and Yoshimori, 2007) . Other studies have found DMOG treatment to induce autophagy to a similar level as that by hypoxia, by the measurement of LC3-puncta (Tracy et al., 2007a) ; however, any further effects of DP on autophagic cell death processes have not yet been reported. After 44 h of prolonged DMOG treatment or growth in a hypoxic chamber, we found that LC3-II levels were consistently induced in PC3AR þ /control cells, however, interestingly, not in PC3AR þ /SIM2s.myc cells (Figures 4d and  ei) . Furthermore, the turnover of SQSTM1/p62 is also attenuated upon stable expression of SIM2s (Figure 4eii , compare lanes 3 and 4). These data strongly suggest that the induction of autophagy is inhibited in SIM2s-expressing cells, concomitant with BNIP3 repression (Figures 4d, e and c, respectively) . Treatment with DP, however, resulted in equal induction of LC3-II protein between control and SIM2s-expressing cells, and, interestingly, to a greater extent than that induced with DMOG treatment in control cells (Figure 4d ), but, on average, less than that with hypoxic (p0.2% O 2 ) treatment (Figure 4ei ). Despite apparent equal induction of LC3-II in control and SIM2s-expressing cells, SIM2s expression is still able to protect cells from prolonged DP-induced autophagic cell death. DP treatment data indicate that alternate mechanisms also exist for SIM2s-mediated protection from prolonged 'hypoxia'-induced cell death. Taken together, these data intimately link increased SIM2s expression with enhanced cell survival during hypoxia-mimetic stress, concomitant with BNIP3 repression, and the attenuation of hypoxia-induced autophagic processes.
SIM2s-mediated repression of BNIP3: correlation with tumourigenesis and patient prognosis? Mechanistic roles for SIM2s and BNIP3 in cancer remain to be fully defined; however, deregulation of both factors are emerging as select solid tumour markers and are associated with poor prognostic outcomes (DeYoung et al., 2002; Halvorsen et al., 2007; Laffin et al., 2008; Burton and Gibson, 2009) . As discussed previously, decreased BNIP3 levels and poor prognosis (Okami et al., 2004; Erkan et al., 2005; Mahon et al., 2007) clearly correlate with elevated SIM2s expression (DeYoung et al., 2002 (DeYoung et al., , 2003b in pancreatic cancer. Moreover, consistent with our findings, others have reported, although the finding is not validated, in RKO colon cancer cells an up-regulation of BNIP3 mRNA following antisense knockdown of endogenous SIM2s, and concomitant loss of cell viability (refer to the supplementary data in Aleman et al., 2005) . Unlike SIM2s (Halvorsen et al., 2007) , there is no understanding of how BNIP3 levels correlate with prostate tumour cell survival or prognosis. Independent studies reported on the 'Oncomine Research' database (http:// www.oncomine.org) offer an insight into the genetic profile of prostate cancer progression, in which SIM2 mRNA levels are significantly elevated in early-stage carcinomas and advanced metastatic and hormone-refractory cancers compared with normal tissue controls, whereas the corresponding BNIP3 levels remain unchanged until the onset of metastatic and hormone-refractory disease (Yu et al., 2004; Varambally et al., 2005) . We propose that SIM2s may function to initially repress and/or inhibit BNIP3 expression in competition with HIF1a with the onset of hypoxic growth conditions, and thus attenuate hypoxia-induced cell death processes, including autophagic cell death, mediated by BNIP3, to allow prostate tumour development. This moderation of HIF1a activities could also allow for alternate pro-tumourigenic HIF1a-mediated pathways to establish (reviewed by Zhou et al., 2006) to advance tumour growth. This putative model for SIM2s moderation of HIF1a activities, as evidenced here by SIM2s cross-talk on the endogenous HRE of hypoxia-inducible BNIP3, provides a possible novel mechanism that allows for the apparent opposing functions of HIF1a (Zhou et al., 2006) in the tumourigenesis of cancers with aberrant levels of SIM2s.
Abbreviations bHLH/PAS, basic helix-loop-helix/PAS; BNIP3, Bcl-2/ adenovirus E1B 19 kDa interacting protein 3; HRE, hypoxia response element; ARNT, aryl hydrocarbon receptor nuclear translocator; RT-PCR, reverse transcription-PCR; ChIP, chromatin immunoprecipitation; DMOG, dimethyloxallyl glycine; DP, dipyridyl.
